Repligen
Yahoo Finance • 3 months ago
Do You Believe in the Growth Prospects of Repligen Corp. (RGEN)?
Conestoga Capital Advisors, an asset management company, released its “SMid Cap Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here. The second quarter of 2024 may be regarded as a time of moderation.... Full story
Yahoo Finance • 7 months ago
Repligen Corp (RGEN) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Shifts and ...
Revenue: Q1 2024 revenue was $151 million, down 17% year-over-year. Book-to-Bill Ratio: 0.99 in Q1, 1.03 over the past 9 months. Net Income: Adjusted net income for Q1 2024 was $16 million, down $20 million from the previous year. Earnings... Full story
Yahoo Finance • last year
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and r... Full story
Yahoo Finance • last year
Repligen Announces Publication of the Company’s 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and r... Full story
Yahoo Finance • last year
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences... Full story
Yahoo Finance • last year
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry’s first hold... Full story
Yahoo Finance • last year
Q3 2023 Repligen Corp Earnings Call
Participants Anthony J. Hunt; CEO & Director; Repligen Corporation Jason K. Garland; CFO; Repligen Corporation Sondra S. Newman; Global Head of IR; Repligen Corporation Brandon Couillard; Equity Analyst; Jefferies LLC, Research Divisio... Full story
Yahoo Finance • last year
Repligen to Report Third Quarter 2023 Financial Results
WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2023 financial results on Tuesday, October 31, 2023. The Company will issue a press relea... Full story
Yahoo Finance • last year
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillo... Full story
Yahoo Finance • last year
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applicationsExpands Repligen’s Fluid Management portfolio, complements single-use bag offering WALTHAM, Mass., Sept. 26, 2023 (GL... Full story
Yahoo Finance • last year
Repligen Appoints Jason K. Garland as Chief Financial Officer
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed Jason K. Garland as Chief Financial Offi... Full story
Yahoo Finance • last year
Repligen Corporation to Present at Wells Fargo Healthcare Conference
WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Confe... Full story
Yahoo Finance • last year
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementationCustomers experience optimized facility equipment installation, footprint, and maintenance req... Full story
Yahoo Finance • 2 years ago
Repligen to Report First Quarter 2023 Financial Results
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2023 financial results on Tuesday, May 2, 2023. The Company will issue a press release b... Full story
Yahoo Finance • 2 years ago
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and... Full story
Yahoo Finance • 2 years ago
Repligen Appoints Martin D. Madaus to Board of Directors
WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus. Dr. Madaus brings to the Repligen bo... Full story
Yahoo Finance • 2 years ago
Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
WALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, 2023. The Company will i... Full story
Yahoo Finance • 2 years ago
Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 41st Annual J.P. Morgan Healthcare... Full story
Yahoo Finance • 2 years ago
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Delivers base business growth of 29% for the quarterExpands Process Analytics portfolio with... Full story
Yahoo Finance • 2 years ago
Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (“Purolite”), for the development and manufacturing... Full story
